Ramsay Health Care Limited

RHC is trading at A$39.83, significantly below the estimated future cash flow fair value of A$53.81 — a discount of more than 20%. This suggests the stock is meaningfully undervalued and offers substantial upside potential for investors with a longer time horizon.

Despite trading below its discounted cash flow estimate, RHC's Price-to-Earnings ratio of 33.5x is expensive relative to the peer average of 26.9x and well above the Global Healthcare industry average of 19.7x, indicating the stock may be overpriced on an earnings basis.

Ramsay Health Care is forecast to grow earnings by 18.5% per annum and EPS by 18.2% per annum, signaling a strong recovery path ahead. This level of projected earnings expansion supports the case for meaningful share price appreciation over the next 12 months.

Despite optimistic earnings growth forecasts, Ramsay's current PE ratio stands at an extraordinarily elevated 1,097x based on trailing figures, and its market cap has declined 14.42% over the past year, raising serious doubts about the reliability of near-term earnings normalisation.

Technical analysis indicates a general buy signal, with the short-term moving average sitting above the long-term average and a buy signal confirmed by the 3-month MACD. The stock is projected to rise approximately 13.29% over the next 3 months, with a 90% probability of reaching A$41.91–A$45.47.

A sell signal was issued from a pivot top point in early July 2025, and the stock has since fallen over 3%. Short-term moving average resistance at approximately A$38.37 and a recommended stop-loss at A$36.45 suggest meaningful downside risk in the near term.